Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex for Reversal of Paralysis in Microlaryngoscopy
NCT03111121Phase 4Completed
- Sponsor
- West Virginia University
- Start
- May 2017
- Primary completion
- Jun 2018
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by West Virginia University. Primary endpoint: Time to Extubation After End of Procedure. Started May 2017; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03111121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03111121.